Akeso Enrolled First Patient for MCRc Akeso Inc. has enrolled its first patient in the registration phase 3 clinical trial AK112-312/HARMONi-GI6 of ivonescimab for its primary treatment of advanced metastatic colorectal cancer (mCRC). The phase 3 trial is a center for the company to achieve pri...
Kraig’s New Addition to the Healthcare Market Announcement Kraig Biocraft Laboratories Inc., a global leader in spider silk technology, has initiated a second parallel production facility, the quick introduction of a new diapausing system, and three new advanced spider silk strains for p...
The ViiV’s Study Indicates the Importance of Choosing Suitable Drugs Announcement ViiV Healthcare, the expert specialist HIV company majorly owned by GSK, along with Shionogi and Pfizer as shareholders, introduced data from its phase 3b volition study, which elaborates that around 89% (n...
Zimmer Biomet to Acquire Monogram Technologies Announcement Zimmer Biomet Holdings, Inc. a popular medical technology and Monogram Technologies, a known orthopedic robotics company, have signed an agreement to acquire outstanding shares of stock of monogram to receive an upfront payment of $4....
Acadia’s R&D Day and Upgradation New Products and Strong R&D Acadia Pharmaceuticals, in its 32 years of business and has currently organized its first R&D day, predicting annual sales of around $12 billion from its investigational chain. Daybue for Rett syndrome and Nuplazid ...
CEL-SCI’s Agreement Approach to a Saudi Arabian Pharma Company Announcement The CEL-SCI corporation (NYSE American CVM) has approached an agreement with a known Saudi Arabian premier healthcare and pharmaceutical company for a strategic partnership that includes commercial and regulatory a...
Nutcracker and Elegen’s Pilot Program Announcement The nutcracker therapeutics a RNA design and manufacturer and Elegen, a DNA manufacturer are introducing a pilot program to describe the company’s first ever full synthetic, cell-free manufacturing platform for RNA-powered personaliz...
‘Weight loss medication’ a New Trend in the Healthcare Market Announcement At the American Diabetes Association’s annual meeting, the need for new weight-loss medicines, primarily for muscle preservation and showing fewer side effects, was the center of concern. The topic enter...
Adopting Precision Diagnostics to Shape the Future of Oncology Therapies A Step Towards the Future of Advanced Therapies The AI-based analysis and digital imaging are believed to be advanced precision oncology therapies for the next generation to achieve potential and access to all patients. The...
Pfizer and Astellas' Positive Results Mark a Significant Improvement Image Credits: The Astellas US Newsroom Announcement Pfizer Inc. and Astellas Pharma Inc. proved their potential with the positive results directly from the overall survival (OS) analysis from its phase 3 study of EMBARK. A st...
